Why the study?
Post-infarction ventricular septal rupture carries high short-term mortality, and management remains challenging due to complex hemodynamics, confusing evidence regarding optimal intervention timing, and a lack of head-to-head trials.
Does surgical repair compared to percutaneous device closure improve 30-day mortality in patients with post-infarction ventricular septal rupture?
Does surgical repair compared to percutaneous device closure improve 30-day mortality in patients with post-infarction ventricular septal rupture?
In patients with post-infarction ventricular septal rupture, there was no significant difference in 30-day mortality between surgical and percutaneous closure, though overall mortality remains high at 44%.
Answers are grounded in this paper and cite their sources.
No mortality difference by closure method; leaves open optimal strategy pending randomized trials in post-infarction VSR.
BACKGROUND: Post-infarction ventricular septal rupture (PIVSR) is a rare mechanical complication, characterized by a dismal prognosis. Despite the widespread timely reperfusion and recent advances in management, short-term mortality of PIVSR remains high. The complexity of the hemodynamic profile, confusing evidence for the optimal timing for intervention, and lack of head-to-head trials, all make the management of such a condition very challenging. METHODS: The database of a tertiary cardiac center was retrospectively analyzed for PIVSR cases through the period from April 2015 to April 2023. Clinical, echocardiographic, and interventional data were explored. The primary outcome was 30-day mortality that was contrasted for surgical versus percutaneous repair. RESULTS: A total of 32 patients with PIVSR were identified. The median age was 65 years, 50% were males, 56% had diabetes, and 50% had cardiogenic shock (CS) on presentation, with a median time of 3 days from acute myocardial infarction (AMI) to PIVSR diagnosis. The median left ventricular ejection fraction (LVEF) was 38%. Culprit vessel patency was acutely restored in 26 patients (81%), while intra-aortic balloon pump (IABP) was inserted in 25 (78%). Upfront insertion of IABP (in the absence of CS) showed a trend towards improved survival (43% vs. 9%). PIVSR was surgically repaired in 15 patients (47%), while 9 (28%) underwent percutaneous device closure, with no significant difference in outcomes and with a median time to intervention of 21 days for both groups. The overall 30-day mortality rate was 44%. Acute kidney injury (AKI) was a significant predictor for 30-day mortality (odds ratio 7.5, 95%CI: 1.3 - 43.7, p = 0.028). CONCLUSION: PIVSR still carries a grave prognosis. Early surgical or percutaneous intervention seems associated with higher mortality, while upfront insertion of IABP for a safe deferral of repair beyond the acute phase may lead to better outcomes. Larger randomized studies are required to dictate the best management.
No takes yet. Share an insight, caveat, or question.
Hussein et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: